{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002390","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.835728+00:00","generated_at":"2026-05-18T06:20:32.173345+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silexion Therapeutics announces 1-for-15 reverse share split to maintain Nasdaq listing","bullets":["Reverse split effective after market close July 28; split-adjusted trading starts July 29 under ticker SLXN.","Every 15 ordinary shares combined into 1; fractional shares rounded up to nearest whole share.","Par value increases from $0.0009 to $0.0135 per share; no action required from shareholders.","Split designed to regain compliance with Nasdaq minimum bid price rule (Listing Rule 5550(a)(2)).","CEO Ilan Hadar states split supports strategic growth initiatives and capital markets positioning."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002390","json":"https://secwatch.observer/filing/0001178913-25-002390.json","markdown":"https://secwatch.observer/filing/0001178913-25-002390.md","text":"https://secwatch.observer/filing/0001178913-25-002390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002390/0001178913-25-002390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002390/zk2533447.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:20:32.173345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}